Log In
Print
BCIQ
Print
Print this Print this
 

deoxycholic acid (Kybella) (ATX-101)

  Manage Alerts
Collapse Summary General Information
Company Kythera Biopharmaceuticals Inc.
DescriptionSynthetic sodium deoxycholate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationBody Fat
Indication DetailsReduce submental (under chin) fat; Treat lipoma
Regulatory Designation

U.S. - Standard Review (Reduce submental (under chin) fat)

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$2,100.0M

$1,723.0M

$330.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today